Genentech (DNA) kept climbing Tuesday, paced by a stellar second-quarter earnings report and the euphoria around its burgeoning wonder drug Avastin.
The stock, which has risen more than 50% this year alone, was recently trading at $84.75 on Instinet, up $1.25, or 1.5%, from its Monday close. The price is 75 times the 2005 earnings guidance that Genentech offered in its second-quarter release and 50 times the 2006 Thomson First Call consensus.
Genentech's second-quarter profit jumped 73% from a year ago to $296.2 million, or 27 cents a share, while earnings before special items came in at $328.6 million, or 30 cents a share. Analysts were looking for 26 cents a share on the latter basis.
Overall revenue was $1.53 billion, up from $1.13 billion a year ago and about $40 million above the Wall Street consensus. The upside was attributable to better-than-expected sales of Avastin, which did $245.7 million in revenue in the period, about $10 million better than expected.In a late conference call Monday, the company's chief financial officer, David Ebersman, chalked up Avastin's performance to growing acceptance among colorectal specialists and increasing use outside of that diagnosis. Ebersman estimated that about 10% of Avastin patients had other diseases. Sales of breast-cancer treatment Herceptin were $152.4 million, about $10 million better than expected, while sales of the lung-cancer drug Tarceva were $70.2 million, about $15 million ahead of forecasts. The main disappointment was Rituxan, which saw sales rise 15% from a year ago to $450.3 million, about $20 million below Wall Street estimates. The company noted on its conference call that Herceptin benefited from increasing use in so-called adjuvant therapy for breast cancer, in which the drug is used to kill cancer cells that might have spread from the breast. The use resulted in a so-called "Dear Doctor" letter in which the company alerted doctors to the possibility of unforeseen consequences of off-label use. The company forecast full-year EPS growth of more than 35% over 2004's 83 cents a share. That implies 2005 earnings of $1.13 a share, matching the Wall Street consensus estimate. Genentech has traditionally been conservative in its profit guidance. "We are actively working with the